FDA Approves Pembrolizumab for High-Risk Bladder Cancer FDA Approves Pembrolizumab for High-Risk Bladder Cancer

Pembrolizumab is now approved for patients with bacillus Calmette-Guerin -unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news